Translational Medicine Series 01 | Using NHP Models to Inform Efficacy Predictions for Autoimmune Therapies

Originally published in Chinese on May 21, 2026. This commentary reflects information available as of May 21, 2026.

Introduction

The “valley of death” between preclinical research and clinical trials remains a major challenge in drug development. Candidates that perform well in rodent studies can encounter insufficient efficacy or unexpected safety findings in clinical trials. In autoimmune and allergic diseases, species differences in target biology and immune responses make translation particularly challenging. How can we bridge this gap? When their pharmacologic relevance and disease features are established, nonhuman primate (NHP) models can provide an important bridge toward more informative predictions of clinical efficacy.

As the global market for autoimmune therapies expands, innovation spans monoclonal and bispecific antibodies, small-molecule Janus kinase (JAK) inhibitors, allosteric tyrosine kinase 2 (TYK2) inhibitors, proteolysis-targeting chimeras (PROTACs), and chimeric antigen receptor T-cell (CAR-T) therapies directed at autoimmune disease targets. Yet autoimmune and allergic diseases involve complex immune networks with considerable redundancy and species-specific biology. These features place demanding requirements on the physiological relevance of early pharmacology studies.

01 Why conventional rodent models face translational challenges

Evolutionary differences in the immune system

Millions of years of divergent evolution have produced important differences between mouse and human immunity. Mouse peripheral blood is typically lymphocyte-predominant, with lymphocytes accounting for approximately 70–80% of leukocytes, whereas human blood is typically neutrophil-predominant, at approximately 50–70%. Differences also extend to T- and B-cell subsets, exhaustion-associated molecules, Fc gamma receptor (FcγR) expression and binding characteristics, and components of cytokine signaling pathways, including IL-4 and IL-17. Differences in the expression and function of costimulatory molecules and immune checkpoints can further affect the response to a human-targeted therapy. Rodent studies provide valuable mechanistic information, but these differences can limit evaluation of particular drug mechanisms. [1]

Cross-species target recognition

Many contemporary autoimmune therapies are humanized monoclonal antibodies, bispecific antibodies, or sequence-specific oligonucleotides such as small interfering RNA (siRNA) and antisense oligonucleotides (ASOs). Antibodies recognize defined protein epitopes, whereas siRNA and ASOs act through complementary nucleic acid sequences. This specificity can restrict activity across species. Some antibodies recognize the corresponding cynomolgus or rhesus macaque target but bind weakly, or not at all, to its rodent counterpart. Without relevant target engagement, conventional mouse studies cannot directly characterize the intended in vivo pharmacodynamic effects or target-mediated toxicity. Candidate-specific binding and functional activity are therefore central to establishing the relevance of an NHP model. [2]

 Figure 1. LPS-responsive genes shared across humans, chimpanzees, and rhesus macaques, with enrichment analyses of immune-related functions, pathways, and regulatory motifs. The results illustrate both conserved and species-specific responses. Source: Barreiro et al. (2010), Figure 1 [4], reproduced from the supplied Chinese article.

Disease pathology and tissue architecture

Allergic asthma and atopic dermatitis (AD) illustrate another challenge. Mouse skin has a thinner epidermis and differs from human skin in tissue architecture and mast-cell distribution. Airway branching and the development of chronic structural remodeling also differ between species. Chemically induced or allergen-induced mouse models can reproduce selected inflammatory responses, but may not capture the full pattern of chronic, relapsing disease regulated by multiple interacting pathways. The aim is to match each model to the disease features and research questions that matter for the candidate therapy. [1,3]

02 Translational advantages of NHP models

HKeyBio focuses on in vivo pharmacology in autoimmune and allergic diseases and develops NHP models as an important component of its translational research platform. Compared with conventional rodent models, pharmacologically relevant NHP models can offer anatomical, physiological, and immunological advantages. These data can strengthen the evidence supporting investigational new drug (IND) submissions when interpreted alongside the rest of the nonclinical package.

Anatomical and physiological relevance

Cynomolgus macaques share important features of skin layering, bronchial anatomy, gastrointestinal physiology, and peripheral immune organs with humans. Gut microbial communities are another relevant dimension, although their composition is influenced by diet and environment. In appropriately characterized models, these similarities support assessment of clinically relevant changes such as airway resistance (RL), dynamic lung compliance (Cdyn), and disruption of colonic mucosal integrity. [3]

Immune response patterns

NHP models enable investigation of Th1/Th17-associated pathways in diseases such as psoriasis and intestinal inflammation, as well as type 2 immune responses relevant to asthma and AD, including Th22-associated biology where appropriate. Following antigen challenge, cytokine profiles and immune-cell kinetics can be compared with the corresponding human disease features. Their value lies in the disease-relevant responses they reproduce; primate immune responses also retain species-specific differences. [3,4]

Pharmacokinetic and pharmacodynamic translation

Similarities in selected metabolic pathways and in neonatal Fc receptor (FcRn)-mediated IgG recycling can make NHP pharmacokinetic and pharmacodynamic (PK/PD) data informative for human translation. FcRn protects IgG from degradation and influences antibody disposition. Together with target engagement, functional potency, exposure, and immunogenicity data, NHP studies can help inform clinical dose projections and reduce uncertainty in first-in-human dose selection. The contribution of each pathway depends on the therapeutic modality and molecule; NHP results do not determine a clinical dose on their own. [2]

03 HKeyBio NHP models for autoimmune and allergic diseases

As a specialist in autoimmune disease models, HKeyBio combines scientific study design with preclinical contract research experience to develop NHP disease models with relevant phenotypes and reproducible readouts. Our portfolio covers key autoimmune and allergic indications and supports customized in vivo efficacy studies for pharmaceutical and biotechnology companies worldwide.

Respiratory disease and allergic asthma

Longitudinal assessment of airway function, including airway hyperresponsiveness (AHR), is an important consideration in asthma model selection. HKeyBio uses allergen-responsive cynomolgus macaques, with scheduled sensitization and repeated airway challenges using allergens such as Ascaris suum or house dust mite (HDM). The model supports assessment of eosinophil infiltration in bronchoalveolar lavage fluid (BALF), allergen-specific serum IgE, airway resistance, and dynamic lung compliance. The measurement method and procedural requirements are specified in the study protocol.

These complementary inflammatory and functional endpoints support evaluation of monoclonal antibodies, bispecific antibodies, and targeted small molecules directed at pathways such as IL-4Rα, IL-5, IL-13, and thymic stromal lymphopoietin (TSLP), where the candidate has relevant activity in the species.

Gastrointestinal disease and colitis

Inflammatory bowel disease (IBD), including ulcerative colitis (UC) and Crohn’s disease (CD), creates a need for large-animal models that address specific translational questions. HKeyBio has developed reproducible chemically induced cynomolgus colitis models, using the induction regimen to control the timing and extent of lesions. Throughout the study, mucosal injury and healing are evaluated using a disease activity index (DAI) incorporating diarrhea, rectal bleeding, and weight loss; high-resolution colonoscopy with endoscopic scoring; and hematoxylin and eosin (H&E) histopathology.

The platform supports studies of candidate therapies targeting TNF-α, α4β7 integrin, JAK signaling, and IL-23. Relating model responses to clinical findings requires consideration of the induction mechanism, candidate pharmacology, and endpoints; an induced colitis phenotype should not be taken to represent all aspects of either UC or CD.

Skin disease including atopic dermatitis and psoriasis

Local tissue microenvironments are especially important in autoimmune and allergic skin disease. HKeyBio uses local administration of selected recombinant cytokines, chemical induction approaches, and other immune stimuli to develop psoriasis-like plaques with erythema, scaling, and skin thickening, or AD-like eczematous phenotypes in cynomolgus macaques. The induction agents discussed in this platform include the hapten DNCB and MC903, a vitamin D₃ analog; these belong to different mechanistic classes and require protocol-specific validation.

Clinical erythema and lesion scores are combined with quantification of tissue T-cell infiltration and local cytokines, including IL-17A, IL-23, IL-4, and IL-31. These readouts enable quantitative assessment of local and systemic pharmacodynamic effects following systemic treatment or topical and transdermal formulations.

HKeyBio has established more than 50 standardized cynomolgus macaque models spanning skin, joints, systemic autoimmunity, ophthalmology, respiratory disease, gastrointestinal disease, and neurology. Selected models are listed below.

Skin and appendage disorders

Joint and connective tissue disorders

Systemic autoimmune disorders

Ophthalmic disorders

Respiratory disorders

Gastrointestinal and metabolic disorders

Neurologic disorders

04 Quality and animal welfare in CRO services

Reproducibility, data integrity, and compliance with applicable standards are central to reliable preclinical research. HKeyBio combines attention to model development with quality management throughout study delivery.

We follow animal welfare standards and provide humane care and environmental enrichment throughout the animals’ lives. Our scientists and veterinarians bring experience from leading contract research organizations in China and overseas. By understanding each candidate’s mechanism of action, we tailor study protocols, select appropriate endpoints including noninvasive assessments where applicable, perform multiplex cytokine analyses, and deliver multidimensional data packages. This integrated support helps Chinese innovators advance global development programs.

Drug development is a demanding journey. In autoimmune and allergic diseases, selecting the right efficacy model provides a practical compass for early translational decisions. As your partner in autoimmune disease modeling, HKeyBio combines high-quality NHP models with rigorous in vivo pharmacology to clarify the path ahead, help bridge the translational valley of death, and support the development of innovative therapies for patients worldwide.

References

[1] Mestas J, Hughes CCW. Of mice and not men: differences between mouse and human immunology. J Immunol. 2004;172(5):2731–2738. Source

[2] Chapman K, Pullen N, Graham M, Ragan I. Preclinical safety testing of monoclonal antibodies: the significance of species relevance. Nat Rev Drug Discov. 2007;6(2):120–126. Source

[3] Coffman RL, Hessel EM. Nonhuman primate models of asthma. J Exp Med. 2005;201(12):1875–1879. Source

[4] Barreiro LB, Marioni JC, Blekhman R, Stephens M, Gilad Y. Functional comparison of innate immune signaling pathways in primates. PLoS Genet. 2010;6(12):e1001249. Source

Author: HKeyBio Marketing Department
Editor: Jing Yan

About HKeyBio

HKeyBio is a preclinical contract research organization specializing in autoimmune and allergic diseases and providing end-to-end in vivo pharmacology services. Its core technical team has more than 20 years of experience across the autoimmune drug development process. The company is ISO 9001 certified and operates an integrated research facility in Suzhou Industrial Park covering molecular biology, cell biology, pathology, small-animal studies, and analytical testing, alongside NHP research sites in Suzhou and Guangxi.

HKeyBio has nearly 60 employees, and its project leads hold master’s or doctoral degrees. The team’s collective experience includes more than 300 autoimmune disease IND submissions, supporting clients in addressing complex challenges throughout development and submission.

· 50+ NHP models of autoimmune and allergic diseases

· 500+ animal models of autoimmune and allergic diseases

· Experience with 300+ autoimmune disease IND submissions

Disclaimer

This article is provided for informational purposes and does not constitute investment advice. Readers are responsible for their own decisions and any associated risks. The views and assessments presented are offered for reference, without any express or implied warranty of accuracy, reliability, or completeness. This publication is intended to share information. If you believe any material infringes your rights, please contact us so that it can be reviewed and removed where appropriate.